Vertex Pharmaceuticals Inc (VRTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $136.56B
Last updated: Nov 17, 2026 at 11:05 AM ET
Vertex Pharmaceuticals Inc (VRTX) Financials: Revenue, Profit and Cash Flow
Vertex Pharmaceuticals reported revenue of $12.00B for the fiscal year ended Dec 31, 2025, up 8.9% from the year before. That year, net income was $3.95B with a net margin of 32.9%, operating cash flow was $3.63B and free cash flow was $3.19B. The quarter ended Sep 30, 2026 had revenue of $3.44B and net income of $653.60M.
Revenue and Margins
The operating margin was 34.8% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $1.70B, a compound annual rate of 24.3%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $12.00B | +8.9% | 86.2% | 34.8% | 32.9% |
| Dec 2024 | $11.02B | +11.7% | 86.1% | -2.1% | -4.9% |
| Dec 2023 | $9.87B | +10.5% | 87.2% | 38.8% | 36.7% |
| Dec 2022 | $8.93B | +17.9% | 87.9% | 48.2% | 37.2% |
| Dec 2021 | $7.57B | +22.1% | 88.1% | 36.7% | 30.9% |
| Dec 2020 | $6.21B | +49.1% | 88.1% | 46.0% | 43.7% |
| Dec 2019 | $4.16B | +36.6% | 86.8% | 28.8% | 28.3% |
| Dec 2018 | $3.05B | +22.5% | 86.6% | 20.8% | 68.5% |
| Dec 2017 | $2.49B | +46.2% | 88.9% | 5.0% | 3.7% |
| Dec 2016 | $1.70B | N/A | 87.6% | 0.6% | -4.9% |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, net income fell 39.5% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.00B | $11.02B | $9.87B | $8.93B | $7.57B | $6.21B | $4.16B | $3.05B | $2.49B | $1.70B |
| Cost of revenue | $1.65B | $1.53B | $1.26B | $1.08B | $904.20M | $736.30M | $547.80M | $409.54M | $275.12M | $210.46M |
| Gross profit | $10.35B | $9.49B | $8.61B | $7.85B | $6.67B | $5.47B | $3.62B | $2.64B | $2.21B | $1.49B |
| Research and development | $4.04B | $8.26B | $3.69B | $2.66B | $3.05B | $1.83B | $1.75B | $1.42B | $1.32B | $1.05B |
| Operating income | $4.17B | -$232.90M | $3.83B | $4.31B | $2.78B | $2.86B | $1.20B | $635.15M | $123.24M | $9.94M |
| Net income | $3.95B | -$535.60M | $3.62B | $3.32B | $2.34B | $2.71B | $1.18B | $2.09B | $91.64M | -$84.03M |
| EBITDA | $4.38B | -$111.80M | $3.99B | N/A | $2.91B | $3.26B | $1.50B | $706.78M | N/A | $75.46M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.44B | $3.33B | $2.99B | $3.19B | $3.08B | $2.96B | $2.77B | $2.91B | $2.77B | $2.65B | $2.69B | $2.52B |
| Gross profit | $2.91B | $2.84B | $2.59B | $2.72B | $2.66B | $2.56B | $2.41B | $2.49B | $2.38B | $2.27B | $2.35B | $2.15B |
| Operating income | $712.90M | $1.25B | $1.14B | $1.21B | $1.19B | $1.15B | $630.10M | $1.03B | $1.12B | -$3.51B | $1.14B | $988.50M |
| Net income | $653.60M | $1.10B | $1.03B | $1.19B | $1.08B | $1.03B | $646.30M | $913.00M | $1.05B | -$3.59B | $1.10B | $968.80M |
Balance Sheet
As of Dec 2025, the balance sheet showed $5.08B in cash and equivalents and no debt.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $25.64B | $22.53B | $22.73B | $18.15B | $13.43B | $11.75B | $8.32B | $6.25B | $3.55B | $2.90B |
| Current assets | $11.20B | $9.60B | $14.14B | $13.23B | $9.56B | $8.13B | $4.82B | $3.84B | $2.65B | $1.83B |
| Cash and equivalents | $5.08B | $4.57B | $10.37B | $10.50B | $6.79B | $5.99B | $3.11B | $2.65B | $1.67B | $1.18B |
| Total liabilities | $6.98B | $6.12B | $5.15B | $4.24B | $3.33B | $3.06B | $2.23B | $1.81B | $1.50B | $1.56B |
| Short-term debt | $0 | $92.30M | $83.70M | $89.40M | $80.20M | $42.40M | $38.79M | $9.82M | $22.53M | $319.43M |
| Long-term debt | $0 | N/A | N/A | N/A | N/A | N/A | N/A | $561.89M | $563.41M | $486.36M |
| Shareholder equity | $18.67B | $16.41B | $17.58B | $13.91B | $10.10B | $8.69B | $6.09B | $4.44B | $2.03B | $1.16B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $32.74B | $27.42B | $26.48B | $26.14B | $24.86B | $24.04B | $22.88B | $22.53B | $22.24B | $20.13B | $23.92B | $22.73B |
| Total liabilities | $11.83B | $7.18B | $7.12B | $7.48B | $7.54B | $6.86B | $6.38B | $6.12B | $6.61B | $5.36B | $5.37B | $5.15B |
| Cash and equivalents | $4.98B | $6.14B | $5.49B | $5.09B | $4.94B | $4.97B | $4.67B | $4.57B | $5.24B | $4.58B | $9.16B | $10.37B |
| Shareholder equity | $20.91B | $20.25B | $19.36B | $18.67B | $17.32B | $17.18B | $16.50B | $16.41B | $15.63B | $14.77B | $18.55B | $17.58B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 87.9% of operating cash flow. Share repurchases came to 63.3% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $3.63B | -$492.60M | $3.54B | $4.13B | $2.64B | $3.25B | $1.57B | $1.27B | $844.94M | $236.10M |
| Capital expenditures | $437.60M | $297.70M | $200.40M | $204.70M | $235.00M | $259.80M | $75.40M | $95.45M | $99.42M | $56.56M |
| Free cash flow | $3.19B | -$790.30M | $3.34B | $3.93B | $2.41B | $2.99B | $1.49B | $1.17B | $745.52M | $179.54M |
| Dividends paid | N/A | N/A | N/A | N/A | $102.00M | $264.95M | $10.05M | $20.84M | $0 | $0 |
| Share repurchases | $2.02B | $1.18B | $427.60M | $0 | $1.43B | $539.10M | $186.00M | $350.04M | $0 | $0 |
| Investing cash flow | -$945.40M | -$3.77B | -$3.14B | -$321.10M | -$340.90M | $99.40M | -$1.24B | -$202.16M | -$483.33M | $51.24M |
| Financing cash flow | -$2.26B | -$1.49B | -$562.20M | -$67.70M | -$1.48B | -$505.30M | $126.80M | -$71.22M | $68.40M | $133.27M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $643.10M | $1.13B | $1.43B | $498.00M | $1.24B | $1.07B | $818.90M | $584.60M | $1.37B | -$3.75B | $1.31B | $234.60M |
| Capital expenditures | $97.30M | $112.20M | $133.40M | $149.40M | $101.80M | $145.70M | $40.70M | $92.60M | $67.70M | $69.00M | $68.40M | $58.10M |
| Free cash flow | $545.80M | $1.01B | $1.29B | $348.60M | $1.14B | $927.40M | $778.20M | $492.00M | $1.30B | -$3.82B | $1.24B | $176.50M |
Frequently Asked Questions About VRTX
What is Vertex Pharmaceuticals' annual revenue?
Vertex Pharmaceuticals reported revenue of $12.00B for the fiscal year ended Dec 31, 2025.
How fast is Vertex Pharmaceuticals' revenue growing?
Revenue was up 8.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 10.4%.
Is Vertex Pharmaceuticals profitable?
Yes. Vertex Pharmaceuticals reported net income of $3.95B for the fiscal year ended Dec 31, 2025, with a net margin of 32.9%.
How much free cash flow does VRTX generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $3.63B minus capital expenditures of $437.60M produced free cash flow of $3.19B.
How much debt does Vertex Pharmaceuticals have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $0, short-term debt of $0 and cash and equivalents of $5.08B.
VRTX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors